04 Feb 2021 | News
Viewpoint: Lessons from Operation Warp Speed can help overcome EU vaccines crisis
As the problem of COVID-19 vaccines supplies so potently illustrates, it is time to rethink the EU’s pandemic preparedness strategy. More support is needed for late stage clinical development and large scale manufacturing
Michel Goldman, former executive director of the EU Innovative Medicines Initiative and professor emeritus at the Université Libre de Bruxelles.
Despite European Medicines Agency approval of three COVID-19 vaccines and the hundreds of millions of doses procured through advance purchase agreements negotiated by the European Commission, member states are facing a shortage of vaccine supplies and falling behind Israel, the UK and the US in terms of vaccines coverage.
SARS-CoV-2 evolution and vaccines: cause for concern? thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Bockarie has been involved in the control of neglected tropical diseases (NTDs) for over 30 years while Karutu has extensive experience designing and leading large-scale public health programs. x
Bockarie holds MSc and PhD degrees from the Liverpool School of Tropical Medicine in the United Kingdom for his research on NTDs and malaria transmission research in Sierra Leone, the Gambia, and Mali. He also undertook postdoctoral studies on NTDs in Australia, Papua New Guinea, Sierra Leone, and the United States.
Bockarie serves as the Regional Director for Africa for the European and Developing Countries Clinical Trials Partnership (EDCTP), where he is also the legal representative of the organisation in South Africa. In his new capacity as a board member, Professor Bockarie will play a crucial role in fostering innovative technical approaches to ending NTDs, as well as exploring newer funding streams for NTD programs.
The SARS-CoV-2 virus that is causing the COVID-19 pandemic is just one of many different viruses in the coronavirus family. Many of these are circulating.
Two HIV vaccine trials launched in Uganda
December 23, 2020 One of the volunteers getting the jab
PrEPVacc is, for the first time, trialing two HIV vaccine regimens in Uganda, and at the same time testing a new form of daily oral pre-exposure prophylaxis (PrEP) against the existing standard for PrEP.
The PrEPVacc trial, testing two ways to prevent HIV at the same time was launched on December 20 and begun giving its first injections and medicines to participants, at the Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, an official statement released on December 20, said.